SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
BlackRock TCP Capital Corp. completed a $535.78 million securitization (CLO Transaction) on May 27, 2026, involving the issuance of secured notes and LLC interests backed by a diversified portfolio of middle-market loans. The transaction included concurrent payoff of a $20+ year loan facility and repayment of $137 million in outstanding credit facility obligations, along with termination of a material loan servicing agreement.
View raw filing on EDGAR →JetBlue disclosed an operational and financial update with updated investor guidance for Q2 2026 results, including revised ranges for ASMs, RASM, CASM Ex-Fuel, fuel price per gallon, and capital expenditures. While technically a pre-earnings guidance update rather than final results, this constitutes a material earnings-related disclosure that would affect investor assessment of the company's financial performance and outlook. The disclosure includes specific forward-looking financial metrics and operational performance data (99.8% completion factor, demand trends, fuel cost recapture expectations).
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder voting results from Northrim BanCorp's May 28, 2026 Annual Meeting. The filing presents detailed vote tallies for four matters: election of 12 directors, approval of the First Amendment to the 2025 Stock Incentive Plan, advisory vote on executive compensation, and ratification of Baker Tilly US LLP as independent auditor. All four proposals passed with substantial majorities, making this a material disclosure of governance outcomes that investors rely upon to assess board composition and compensation oversight.
View raw filing on EDGAR →Disciplined Growth Acquisition Corp completed a $150 million initial public offering as a special purpose acquisition company (SPAC), establishing the foundational capital structure and governance framework for future business combination activity through multiple definitive agreements including underwriting, trust, registration rights, and sponsor arrangements.
View raw filing on EDGAR →The company issued 345,000 Private Placement Units at $10.00 per unit ($3.45 million) and 1,100,000 founder shares at approximately $0.004 per share to the Sponsor, Maxim, and at-risk capital investors pursuant to Section 4(a)(2) exemptions, representing classic dilutive private placements typical of SPAC formation.
View raw filing on EDGAR →Five directors—John W. Heilshorn, Aaron Spool, Michael Faber, John Ziegelman, and Jay Gettenberg—were appointed to the board effective May 27, 2026 in connection with the IPO, with committee assignments made on May 28, 2026.
View raw filing on EDGAR →Flutter Entertainment held its Annual General Meeting on May 29, 2026, with voting results on eight proposals including director elections, executive compensation advisory vote, articles amendments, auditor ratification, and share issuance authorities. Notably, Proposal 3c regarding preferred share issuance amendment failed to achieve the required 75% supermajority threshold, affecting the company's governance and capital structure flexibility.
View raw filing on EDGAR →Hadron Energy completed a business combination with GigCapital7 on May 22, 2026, resulting in a change of control and transformation from a shell company to an operating company. The combined entity listed on Nasdaq under ticker 'HDRN' with 71.5M shares outstanding and a capital structure reflecting 77.2% ownership by former Hadron insiders and 23% by former GigCapital7 shareholders.
View raw filing on EDGAR →BPM LLP was engaged as the independent registered public accounting firm, effective April 24, 2026, replacing WithumSmith+Brown, PC in connection with the closing of the business combination.
View raw filing on EDGAR →Five executive officers were appointed effective upon the business combination closing on May 22, 2026: Samuel Gibson as CEO, Rahul Shukla as CFO, Ken Canavan as COO, Ross T. Ridenoure as Chief Nuclear Officer, and Dr. Andrew M. Ward as CTO. Additionally, nine directors were appointed to the board.
View raw filing on EDGAR →The Amended and Restated Certificate of Incorporation and Bylaws were adopted following the business combination closing, materially modifying shareholder rights through elimination of redemption rights, authorization of new share capital structure, classified board provisions, exclusive forum selection, and transfer restrictions on founder/employee shares.
View raw filing on EDGAR →Aircastle entered into a $375 million unsecured term loan credit agreement with an option to increase to $425 million, a material financing transaction affecting the company's capital structure and liquidity.
View raw filing on EDGAR →Lumentum is issuing approximately 5.0 million shares of common stock in a privately-negotiated exchange with convertible noteholders, resulting in incremental dilution of approximately 0.8 million shares. The transaction is structured as an unregistered private placement under Section 4(a)(2) of the Securities Act, which is the hallmark of a dilutive equity issuance. This materially affects shareholder ownership and is a significant capital structure event.
View raw filing on EDGAR →Srinivas Attili, Executive Vice President of the Civilian Business Group, stepped down from his role effective May 29, 2026 and will depart the Company on or about June 12, 2026. While the disclosure mentions severance compensation, the principal disclosed action is the departure of a named executive officer from the Company, making this an exec_departure event. The departure of an EVP responsible for a major business segment is material to investors.
View raw filing on EDGAR →The principal disclosed action is the resignation of Tawn Kelley as Chair and Board member, effective immediately on May 31, 2026. While the filing also mentions the appointment of Michael Berman as Chair and Gary Robinette to the Nominating and Governance Committee, the central event is Kelley's departure from the Board. The resignation of a Chair is material to investors as it affects corporate governance and leadership structure.
View raw filing on EDGAR →IN8bio entered into a Capital on Demand Sales Agreement with JonesTrading on June 1, 2026, establishing an at-the-market offering program under which the Company may issue and sell shares of common stock at its discretion.
View raw filing on EDGAR →IN8bio terminated its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald, which had been a material financing mechanism established in November 2022, eliminating the Company's ability to raise capital through that at-the-market offering program.
View raw filing on EDGAR →The Company disclosed an investor presentation describing its business and "Path Forward Plan update" via Regulation FD. While the disclosure itself is routine (Item 7.01 furnishing), the substantive content—a strategic plan update—could be material to investors assessing the Company's direction and operational strategy. However, without access to the actual presentation content, the materiality and specific event type cannot be definitively determined; this is classified as other_material pending review of Exhibit 99.1.
View raw filing on EDGAR →Eloxx Pharmaceuticals issued prefunded warrants to purchase 54,076,677 shares of common stock at $0.01 per share in an unregistered private placement relying on Sections 4(a)(2) and 3(a)(9) exemptions, with subsequent exercises and exchanges materially diluting existing shareholder equity and voting power.
View raw filing on EDGAR →The Board appointed Stephen W. Webster and Nina Kjellson as directors on May 27, 2026, filling vacancies and reducing board size from six to five members; both appointees were assigned to specific board committees and received equity grants of 13,587 option shares each.
View raw filing on EDGAR →The company implemented a 1-for-11 reverse stock split and reduced authorized shares from 500 million to 100 million, both approved by stockholders and effectuated via Certificate of Amendment filed May 29, 2026, materially altering the capital structure and per-share metrics.
View raw filing on EDGAR →The company disclosed a material modification to the rights of security holders, with details incorporated by reference from Item 5.03 (Amendments to Articles of Incorporation or Bylaws); the specific nature of the modification cannot be determined without access to the referenced Item 5.03 content.
View raw filing on EDGAR →Taylor Morrison Home Corp entered into a definitive merger agreement with Berkshire Hathaway on May 31, 2026, whereby Berkshire's merger subsidiary will merge with Taylor Morrison, with Taylor Morrison continuing as a wholly owned subsidiary of Berkshire at $72.50 per share in cash. The Board unanimously approved the transaction and recommended stockholder adoption, resulting in a change of control and delisting from NYSE.
View raw filing on EDGAR →The company announced updated clinical trial data for drug candidates EIK1001 and EIK1003 presented at ASCO 2026, which is material to investor assessment of the company's pipeline progress and regulatory prospects.
View raw filing on EDGAR →HCI Group entered into comprehensive reinsurance agreements for its four insurance subsidiaries covering June 1, 2026 through May 31, 2027, with total net consolidated reinsurance premiums of approximately $381.2 million to third parties. While this is a material definitive agreement (Item 1.01) involving significant financial commitments and risk transfer arrangements across three reinsurance towers, it does not fit cleanly into the ma_activity category, which typically covers acquisitions, dispositions, mergers, or changes of control. This is a routine but material operational reinsurance placement that would affect investor assessment of the company's catastrophe risk mitigation strategy and financial obligations.
View raw filing on EDGAR →Jade Biosciences disclosed interim Phase 1 trial results for JADE101, a novel monoclonal antibody candidate for IgAN treatment, showing favorable safety, potent IgA reductions (approximately 70% at the 700 mg dose), and a differentiated pharmacokinetic profile. The results were presented via conference call and webcast and represent a material clinical development milestone affecting investor assessment of the company's pipeline progress and product viability.
View raw filing on EDGAR →Teleflex announced a $500 million private offering of Senior Notes due 2032 to refinance its 4.625% Senior Notes due 2027, materially affecting the company's capital structure and debt maturity profile.
View raw filing on EDGAR →Thomas M. O'Brien was appointed as President and Chief Executive Officer of BCB Bancorp, Inc. and BCB Community Bank effective June 1, 2026, with board service. While the filing also discloses compensatory arrangements (restricted stock grant of $8,000,000 value, base salary of $400,000, severance terms), the principal disclosed action is the appointment of a new principal executive officer. This is material to investors as it represents a significant leadership change at the company.
View raw filing on EDGAR →Strategy Inc disclosed multiple material operational updates including ATM program activity generating $128.3M in net proceeds, bitcoin sales of $2.5M, dividend declarations across five preferred stock series, and maintenance of an $900M USD Reserve. These disclosures collectively constitute material information about the registrant's financing, asset management, and shareholder distributions.
View raw filing on EDGAR →Rallybio Corporation entered into an Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics on May 31, 2026, whereby Avenzo will survive as a wholly-owned subsidiary of Rallybio. The transaction represents a material change of control with Avenzo equityholders expected to own approximately 56.6% of the combined company post-closing.
View raw filing on EDGAR →Concurrent with the merger, Rallybio is issuing unregistered Avenzo Class A common stock in private placements exempt under Section 4(a)(2) and Regulation D, materially diluting existing shareholder ownership.
View raw filing on EDGAR →Rallybio amended employment and separation agreements for named executives Stephen Uden, Jonathan Lieber, and Steven Ryder to modify their change-of-control compensation, benefits, and equity treatment in connection with the merger.
View raw filing on EDGAR →Anton Nikodemus was appointed as Executive Vice President and Chief Operating Officer, effective June 15, 2026, with a base salary of $550,000, performance bonus, equity awards, and severance provisions.
View raw filing on EDGAR →Welltower announced an increase in its quarterly common stock dividend from an implied prior level to $0.85 per share, effective Q2 2026. While dividend announcements are material to investors and affect total shareholder return expectations, this disclosure does not fit cleanly into the standard taxonomy categories (earnings_release, exec_compensation, etc.). The announcement is a capital allocation decision rather than a financial result, executive action, or compensation arrangement, making "other_material" the most appropriate classification.
View raw filing on EDGAR →Wael Mohamed was appointed Chief Executive Officer effective June 1, 2026, succeeding Corey Thomas who transitioned to Executive Chairman. The appointment includes compensatory arrangements including RSU grants, performance bonuses, and severance terms.
View raw filing on EDGAR →AirJoule Technologies entered into a Securities Purchase Agreement on May 28, 2026 to sell 3,658,536 shares of Class A common stock at $4.10 per share through a registered direct offering, raising approximately $14.2 million in net proceeds. The offering was announced via press release and represents a significant capital raise with material equity dilution to existing shareholders.
View raw filing on EDGAR →AirJoule Technologies held its 2026 Annual Meeting of Shareholders on May 28, 2026, with voting results disclosed for the election of two Class II directors (Thomas E. Murphy and Denise B. Sterling) and ratification of Deloitte & Touche LLP as independent auditor, presented with detailed vote tallies.
View raw filing on EDGAR →This is a material asset purchase agreement where Edgewise Therapeutics is selling its neuromuscular program (including the sevasemten compound) to Servier Pharmaceuticals for $1.55 billion upfront plus up to $1.1 billion in milestone payments. The transaction constitutes a substantial disposition of a core program and is disclosed under Item 1.01 (Entry into a Material Definitive Agreement), which is the standard Item for M&A activity. The magnitude ($1.55B+ in consideration) and strategic significance (sale of a major drug candidate) make this clearly material to investors.
View raw filing on EDGAR →IFF entered into a definitive Transaction Agreement on May 28, 2026, to sell its Food Ingredients business to Foxtrot US Bidco, Inc. (a CVC Capital Partners affiliate) for approximately $4.3 billion in enterprise value, with IFF receiving ~$3.8 billion in net cash proceeds and retaining a ~9.9% minority equity stake in the divested business.
View raw filing on EDGAR →Bogota Financial Corp. entered into an Agreement and Plan of Merger whereby GSL Savings Bank will merge into Bogota Savings Bank, with the Bank as the surviving institution. The transaction contemplates closing in the second half of 2026, involves issuance of additional common stock, and includes customary merger representations, warranties, covenants, and a $750,000 termination fee.
View raw filing on EDGAR →The Company disclosed the employment agreement terms for Mr. Giancola, including a base salary of $250,000, minimum bonus opportunity of 20%, severance provisions, and change-of-control protections contingent on the merger closing.
View raw filing on EDGAR →Brian Barr was appointed as Chief Operating Officer, succeeding John Orr. The appointment includes detailed compensation terms including a $600,000 base salary, $2.5M long-term incentive plan target, $1.26M promotional award, and $2M retention bonus.
View raw filing on EDGAR →Whirlpool announced a $1.5 billion private placement of Senior Secured Second Lien Notes (due 2031 and 2034) to qualified institutional buyers under Rule 144A and Regulation S. While this is a debt issuance rather than equity, the scale ($1.5B) and the concurrent tender offer for existing notes suggest material refinancing activity. However, the event is primarily a debt offering with a tender offer component, which does not fit cleanly into the dilutive_issuance category (typically equity-focused) or ma_activity. The most defensible classification is dilutive_issuance given the capital-raising nature and materiality, though other_material would also be reasonable.
View raw filing on EDGAR →Four Corners Property Trust entered into a Purchase and Sale Agreement on May 29, 2026, to acquire up to 102 veterinary properties for up to $268.0 million, constituting a material acquisition that will significantly expand the company's asset base and investment portfolio.
View raw filing on EDGAR →The filing discloses an unregistered sale of 34,106 Class ER-A Common Shares for $1,000,000 gross proceeds under a continuous private placement offering of up to $2.165 billion, conducted pursuant to Section 4(a)(2) and Regulation D Rule 506(c). This is a classic dilutive equity issuance that would materially affect investor assessment of share dilution and capital structure, particularly given the large authorized offering size and the Company's explicit acknowledgment in forward-looking statements that "future sales or issuances of our Common Shares...could cause the value of our Common Shares to decline and could result in dilution."
View raw filing on EDGAR →Timothy L. Prindle was elected Chairman of the Board in addition to his existing roles as President and CEO, representing a material change in executive leadership structure. The Board's deliberate decision to combine the Chairman and CEO roles, along with the concurrent appointment of William B. Crompton, III as Lead Independent Director to provide independent oversight, constitutes a significant governance event that would affect a reasonable investor's assessment of the company's leadership and control structure.
View raw filing on EDGAR →Edward V. Weller, the Chief Financial Officer and a named executive officer identified in the Bank's 10-K, has notified the Bank of his intent to retire effective October 20, 2026. The disclosure centers on the departure of a senior executive officer, making this an exec_departure event. The CFO role is material to investors' assessment of the registrant's financial management and governance.
View raw filing on EDGAR →This Item 5.07 disclosure presents the results of Great Elm Capital Corp.'s 2026 annual stockholder meeting held on May 29, 2026, including voting tallies for the election of directors (Mark Kuperschmid and Richard Cohen) and ratification of Deloitte & Touche LLP as independent auditor. The tabulated vote counts and outcomes are the core content of a shareholder vote results disclosure, which is material to investors assessing corporate governance and board composition.
View raw filing on EDGAR →Manhattan Associates announced a 6% global headcount reduction with estimated cash charges of $7–9 million in Q2 2026 for severance and termination benefits, representing a material restructuring event affecting the company's cost structure and near-term financial results.
View raw filing on EDGAR →Fulcrum announced discontinuation of its pociredir program for sickle cell disease and initiation of a comprehensive strategic review. While this represents a material operational change affecting the company's pipeline and strategic direction, it does not fit neatly into more specific categories (not a restatement, impairment charge, going-concern disclosure, or M&A activity per se). The strategic review language suggests potential future M&A or restructuring, but the disclosed event itself is the program discontinuation and review initiation.
View raw filing on EDGAR →